Hong Kong Consumer Services Stock News

SEHK:1138
SEHK:1138Oil and Gas

A Look At COSCO SHIPPING Energy Transportation’s Valuation After Record Profit Outlook For 2025 And Early 2026

Record profit outlook puts recent share gains in focus COSCO SHIPPING Energy Transportation (SEHK:1138) is in the spotlight after projecting record profit for 2025 and signaling strong year-on-year growth for early 2026, supported by resilient oil transport demand and constrained shipping capacity. See our latest analysis for COSCO SHIPPING Energy Transportation. Investors have responded quickly to COSCO SHIPPING Energy Transportation’s outlook, with a 30 day share price return of 33.68% and...
SEHK:631
SEHK:631Machinery

Assessing Sany Heavy Equipment International Holdings (SEHK:631) Valuation After New CICC Financial Product Subscription Plan

Why Sany Heavy Equipment International Holdings (SEHK:631) is Back on Investor Radar Sany Heavy Equipment International Holdings (SEHK:631) has disclosed plans to subscribe for financial products from CICC Group, highlighting its capital allocation choices for investors watching how the company manages liquidity. See our latest analysis for Sany Heavy Equipment International Holdings. The intent to place funds into CICC Group products comes at a time when Sany Heavy Equipment International...
SEHK:9995
SEHK:9995Biotechs

RemeGen (SEHK:9995) Is Down 7.8% After US$650m AbbVie PD-1/VEGF Licensing Deal News - Has The Bull Case Changed?

Earlier in January 2026, AbbVie and RemeGen announced an exclusive licensing agreement for RC148, a PD-1/VEGF bispecific antibody for advanced solid tumors, giving AbbVie rights outside Greater China in exchange for an upfront US$650 million payment plus very large potential milestone payments and tiered double-digit royalties. The deal not only validates RemeGen’s oncology platform but also links RC148 to AbbVie’s antibody-drug conjugate pipeline, broadening future combination therapy...
SEHK:992
SEHK:992Tech

Is Lenovo Group (SEHK:992) Pricing Reflect A Double Digit Discount To Intrinsic Value Estimates

If you are wondering whether Lenovo Group's current share price lines up with its underlying value, this breakdown is designed to give you a clear, numbers first view. Lenovo's shares last closed at HK$8.84, with returns of 0.5% decline over 7 days, 5.2% decline over 30 days, 7.4% decline year to date and 3.0% decline over the past year, set against longer term returns of 58.5% over 3 years and 20.1% over 5 years. Those mixed returns have arrived as Lenovo continues to attract attention in...
SEHK:762
SEHK:762Telecom

A Look At China Unicom (Hong Kong) (SEHK:762) Valuation After Dong Xin’s Dual Chairman And CEO Appointment

Leadership change and why it matters for China Unicom (Hong Kong) China Unicom (Hong Kong) (SEHK:762) has appointed Dong Xin as both Chairman and Chief Executive Officer, a dual role that often prompts investors to reassess how leadership, governance and execution might align. See our latest analysis for China Unicom (Hong Kong). At a share price of HK$7.77, China Unicom (Hong Kong) has a 1-day share price return of 1.97%, while the 90-day share price return of 17.25% decline sits alongside a...
SEHK:2228
SEHK:2228Life Sciences

Assessing XtalPi Holdings (SEHK:2228) Valuation After AI Partnerships And Revenue Growth Attract Market Attention

Why XtalPi Holdings Is On Investors’ Radar Today XtalPi Holdings (SEHK:2228) is drawing fresh attention as its AI powered drug discovery services support robust revenue growth and key healthcare AI partnerships, while some investors remain cautious about margins and cash flow. See our latest analysis for XtalPi Holdings. That stronger interest is showing up in the numbers, with a 1 month share price return of 41.89% at a latest share price of HK$13.48 and a 1 year total shareholder return of...
SEHK:2171
SEHK:2171Biotechs

How CARsgen’s Solid Tumor CAR T Virus Combo Trial Could Reshape Its Story for Investors (SEHK:2171)

Dispatch Bio and CARsgen Therapeutics Holdings announced a clinical collaboration to run a Phase 1 trial in China evaluating DISP-11, combining Dispatch’s Flare platform and DV-10 virus with CARsgen’s approved BCMA-targeting CAR T therapy zevorcabtagene autoleucel in patients with epithelial solid tumors. This pairing of a tumor-specific virus that “paints” a synthetic antigen with an existing CAR T-cell therapy aims to open an immunotherapy path for solid tumors, where treatment options...
SEHK:1258
SEHK:1258Metals and Mining

Why China Nonferrous Mining (SEHK:1258) Is Down 5.0% After Resuming Full Output And Issuing 2026 Guidance

China Nonferrous Mining Corporation Limited recently reported that rehabilitation of the main and auxiliary shafts at Chambishi Southeast Mine was completed in December 2025, allowing the operation to resume full production on 1 January 2026. Alongside this, the company issued 2026 production guidance outlining approximately 484,000 tonnes of overall copper output and diversified by-products, giving investors clearer visibility into future operating volumes and product mix. We will now...
SEHK:358
SEHK:358Metals and Mining

Assessing Jiangxi Copper (SEHK:358) Valuation After Long Term Metal Supply Agreements With China Ordins Group

Jiangxi Copper (SEHK:358) has signed multi year procurement and sales cooperation agreements with China Ordins Group, covering mutual supply of copper, nickel, aluminium, zinc, tin and other metals under market based pricing from 2026 to 2028. See our latest analysis for Jiangxi Copper. The new multi year agreements arrive after a strong run in the shares, with a 30 day share price return of 21.43% and a 90 day share price return of 34.58%. The 1 year total shareholder return of around 3.7x...
SEHK:1208
SEHK:1208Metals and Mining

Why MMG (SEHK:1208) Is Up 10.7% After Unveiling 2026 Cost Guidance Highlighting Rosebery’s Negative C1 Zinc Costs

MMG Limited recently reported its fourth-quarter and full-year 2025 production results alongside detailed 2026 production and C1 cost guidance for its major copper and zinc operations, including Las Bambas, Kinsevere, Khoemacau, Dugald River and Rosebery. A distinctive feature of the update is Rosebery’s 2026 C1 cost outlook, where by-product credits are expected to drive zinc cash costs below zero on a per‑pound basis. We’ll now examine how MMG’s 2026 cost and production guidance,...
SEHK:826
SEHK:826Metals and Mining

Does Fusion Materials Lab Entry Recast Tiangong International’s Advanced Metallurgy Ambitions (SEHK:826)?

Tiangong International announced that its subsidiary Jiangsu Tiangong Aihe Technology was approved on 16 January 2026 to join the Institute of Energy, Hefei Comprehensive National Science Center’s joint laboratory for developing fusion-oriented advanced metallic materials, including large-scale powder metallurgy 304B7 high-boron steel and new neutron shield steel. This collaboration gives Tiangong direct involvement in controlled nuclear fusion material research, potentially broadening...
SEHK:6993
SEHK:6993Household Products

Blue Moon Group Holdings (SEHK:6993) Valuation After Guidance For A 50% Cut In 2025 Losses

Blue Moon Group Holdings (SEHK:6993) issued new earnings guidance, telling investors it expects at least a 50% reduction in its 2025 loss compared with the HK$749.3 million loss recorded for 2024. See our latest analysis for Blue Moon Group Holdings. That guidance landed alongside a 1 day share price return of 4.56% and a year to date share price return of 8.76% at HK$2.98. However, the 1 year total shareholder return of 13.58% and 5 year total shareholder return of 77.98% show that longer...
SEHK:460
SEHK:460Pharmaceuticals

A Look At Sihuan Pharmaceutical (SEHK:460) Valuation After New Polylactic Acid Filler Approvals

Why Sihuan Pharmaceutical’s latest filler approval matters for investors Sihuan Pharmaceutical Holdings Group (SEHK:460) recently reported that six additional specifications of its polylactic acid facial filler received approval from China’s National Medical Products Administration, expanding its medical aesthetics product range to allow more tailored anti aging treatments. See our latest analysis for Sihuan Pharmaceutical Holdings Group. The latest PLLA filler approvals come after a strong...
SEHK:853
SEHK:853Medical Equipment

Assessing MicroPort Scientific (SEHK:853) Valuation After Turnaround Profit Guidance For 2025

Why MicroPort Scientific’s latest guidance matters MicroPort Scientific (SEHK:853) has told investors it expects a turnaround to profitability in 2025, guiding to net profit of at least US$20 million after reporting an audited 2024 net loss of about US$268 million. See our latest analysis for MicroPort Scientific. The guidance appears to have arrived alongside a shift in sentiment, with a 1 month share price return of 18.17% and year to date share price return of 19.81%. The 1 year total...
SEHK:1024
SEHK:1024Interactive Media and Services

Kuaishou’s Multi‑Currency Bonds and Kling AI User Surge Might Change The Case For Investing In Kuaishou Technology (SEHK:1024)

Kuaishou Technology recently completed multi-currency fixed-rate senior unsecured bond offerings, raising about US$1.49 billion and CNY 3.50 billion with maturities extending to 2036, while reporting December 2025 monthly revenue above US$20 million. At the same time, its AI video-generation tool Kling surpassed 12 million monthly active users, underscoring how artificial intelligence is becoming a core pillar of Kuaishou’s business model and product appeal. We’ll now examine how the...
SEHK:175
SEHK:175Auto

The Bull Case For Geely Automobile Holdings (SEHK:175) Could Change Following Its New “One Geely” 2030 EV Blueprint

Earlier this year, Geely Holding Group outlined a new “One Geely” blueprint targeting global vehicle sales above 6.5 million by 2030, with new energy vehicles projected to account for three-quarters of volumes and overseas markets contributing more than one-third of deliveries. By tightly coordinating its brands and technology programs around green, intelligent and autonomous driving solutions, Geely is signaling a push to operate more like an integrated global technology group than a...